Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
Clinical trials of FDA-approved GLP-1 medications have shown average weight loss of roughly 15 to 20 percent over about a year, depending on the drug and dose
In preclinical animal studies on obese mice and rats, retatrutide led to body-weight reductions of 2030 % within 12 weeks, significantly stronger than semaglutide comparison groups
While food cannot replicate the potency or duration of GLP-1 medications, research suggests that the foods we choose at each meal can stimulate different amounts of GLP-1 release
Methodology This survey was commissioned by Sunlight.com in September 2025 and conducted through Pollfish
There are zero administrative fees or PMPM fees charged to employers
Semaglutide is typically started at a low dose and titrated gradually upward to minimize side effects, which most commonly include nausea, mild digestive discomfort, and fatigue, particularly in the early weeks of treatment
